Iv A, L.P.Clarus Iv B, L.P.... Net Worth

The estimated Net Worth of Iv A, L.P.Clarus Iv B, L.P.... is at least $9.52 Mille dollars as of 12 November 2019. Iv P owns over 250,000 units of Galera Therapeutics Inc stock worth over $9,522 and over the last 5 years Iv sold GRTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Iv P GRTX stock SEC Form 4 insiders trading

Iv has made over 1 trades of the Galera Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Iv bought 250,000 units of GRTX stock worth $3,000,000 on 12 November 2019.

The largest trade Iv's ever made was buying 250,000 units of Galera Therapeutics Inc stock on 12 November 2019 worth over $3,000,000. On average, Iv trades about 250,000 units every 0 days since 2019. As of 12 November 2019 Iv still owns at least 130,444 units of Galera Therapeutics Inc stock.

You can see the complete history of Iv P stock trades at the bottom of the page.

Insiders trading at Galera Therapeutics Inc

Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ... e Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.

What does Galera Therapeutics Inc do?

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Complete history of Iv P stock trades at Galera Therapeutics Inc

Galera Therapeutics Inc executives and stock owners

Galera Therapeutics Inc executives and other stock owners filed with the SEC include:

• J. Mel Sorensen,
  President, Chief Executive Officer, Director
• Christopher Degnan,
  Chief Financial Officer
• Robert Beardsley,
  Chief Operating Officer
• Dr. J. Mel Sorensen,
  CEO, Pres & Director
• Christopher Degnan,
  CFO & Sec.
• Dr. Robert A. Beardsley,
  Co-Founder & COO
• Arthur Fratamico,
  Chief Business Officer
• Jon Holmlund,
  Chief Medical Officer
• Lawrence Alleva,
  Independent Director
• Michael Powell,
  Independent Chairman of the Board
• Emmett Cunningham,
  Director
• Kevin Lokay,
  Independent Director
• Linda West,
  Independent Director
• Joel Sussman,
  Chief Accounting Officer
• Mark J. Bachleda M.B.A., Pharm.D.,
  Chief Commercial Officer
• Arthur J. Fratamico,
  Chief Bus. Officer
• Dr. Jon T. Holmlund,
  Chief Medical Officer
• Jennifer Evans Stacey Esq.,
  Chief Legal & Compliance Officer and Sec.
• Dr. Dennis P. Riley Ph.D.,
  Chief Scientific Officer
• Joel F. Sussman,
  Chief Accounting Officer & Treasurer
• Bioventures Ltd Novartis Ag...,
  
• Chris Degnan,
  Chief Financial Officer
• Jason Fuller,
  Director
• Iv A, L.P.Clarus Iv B, L.P....,
  
• Group Inc Blackstone Group ...,
  
• Clarus Gp L.P.Blackstone Cl...,
  
• Enterprise Associates 14, L...,
  
• Venture Partners Ix, L.P.So...,
  
• Dennis Riley,
  Chief Scientific Officer
• Holdings A/S Novo,
  10% owner
• Mark Bachleda,
  Chief Commercial Officer
• Jennifer Evans Stacey,
  See Remarks
• Yair Schneid,
  10% owner
• Eugene P. Kennedy,
  Chief Medical Officer
• Mel Sorensen,
  President and CEO